Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
China · Delayed Price · Currency is CNY 54.84
-0.54 (-0.98%)
Apr 28, 2026, 3:00 PM CST
SHA:600276 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 8,119 | 7,711 | 6,337 | 4,302 | 3,906 | 4,530 |
Depreciation & Amortization | 843.38 | 843.38 | 776.03 | 704.64 | 577.89 | 520.41 |
Other Amortization | 99.09 | 99.09 | 94.79 | 89.3 | 66.26 | 20.33 |
Loss (Gain) From Sale of Assets | -4.05 | -4.05 | -5.4 | -3.16 | -5.47 | -3.37 |
Asset Writedown & Restructuring Costs | 72.26 | 72.26 | 4.94 | 76.21 | 131.24 | -117.52 |
Loss (Gain) From Sale of Investments | -116.09 | -116.09 | -132.5 | 35.62 | -533.84 | -169.57 |
Provision & Write-off of Bad Debts | 19.02 | 19.02 | -28.67 | -15.77 | 26.02 | -3.87 |
Other Operating Activities | 226.29 | 403.23 | 30.83 | 17.02 | -67.79 | -27.8 |
Change in Accounts Receivable | -1,097 | -1,097 | -375.7 | 2,036 | -2,285 | -868.27 |
Change in Inventory | -479.24 | -479.24 | -135.63 | 129.11 | -52.68 | -631.22 |
Change in Accounts Payable | 4,135 | 4,135 | 671.41 | 315.32 | -511.05 | 809.7 |
Change in Other Net Operating Assets | 53.02 | 53.02 | 209.26 | 55.47 | 34.98 | 253.16 |
Operating Cash Flow | 11,467 | 11,235 | 7,423 | 7,644 | 1,265 | 4,219 |
Operating Cash Flow Growth | 70.55% | 51.36% | -2.89% | 504.12% | -70.01% | 22.93% |
Capital Expenditures | -2,965 | -2,962 | -1,969 | -1,484 | -1,992 | -1,665 |
Sale of Property, Plant & Equipment | 28.2 | 18.91 | 21.9 | 20.18 | 20.21 | 16.11 |
Divestitures | - | - | - | - | 36.05 | - |
Investment in Securities | -29.3 | 151 | -17.2 | 2,590 | 2,160 | 842.49 |
Other Investing Activities | 33.22 | 51.49 | 52.51 | 95.51 | 166.49 | 259.77 |
Investing Cash Flow | -2,933 | -2,741 | -1,912 | 1,222 | 390.29 | -546.26 |
Short-Term Debt Issued | - | - | - | - | 1,260 | - |
Long-Term Debt Issued | - | 1,496 | 799.91 | 21.1 | - | - |
Total Debt Issued | 1,795 | 1,496 | 799.91 | 21.1 | 1,260 | - |
Long-Term Debt Repaid | - | -1,544 | -847.28 | -1,315 | -36.28 | -31.05 |
Net Debt Issued (Repaid) | -48.69 | -48.23 | -47.38 | -1,294 | 1,224 | -31.05 |
Issuance of Common Stock | 10,770 | 10,770 | - | - | - | - |
Repurchase of Common Stock | -978.15 | -978.15 | -228.43 | -827.26 | -1,066 | -235.16 |
Common Dividends Paid | -1,284 | -1,284 | -1,275 | -1,023 | -1,016 | -1,066 |
Other Financing Activities | -201.95 | -677.76 | - | - | 538.86 | 334.14 |
Financing Cash Flow | 8,257 | 7,782 | -1,551 | -3,144 | -318.77 | -998.32 |
Foreign Exchange Rate Adjustments | -739.46 | -360.13 | 7.4 | 12.53 | 80.5 | -16.87 |
Net Cash Flow | 16,052 | 15,916 | 3,968 | 5,734 | 1,417 | 2,657 |
Free Cash Flow | 8,502 | 8,273 | 5,454 | 6,160 | -726.91 | 2,554 |
Free Cash Flow Growth | 84.30% | 51.71% | -11.47% | - | - | -11.24% |
Free Cash Flow Margin | 26.11% | 26.16% | 19.49% | 26.99% | -3.42% | 9.86% |
Free Cash Flow Per Share | - | 1.27 | 0.86 | 0.97 | -0.11 | 0.40 |
Cash Income Tax Paid | 2,833 | 2,787 | 2,290 | 1,568 | 1,631 | 1,607 |
Levered Free Cash Flow | 6,308 | 5,859 | 4,391 | 4,866 | -2,030 | 1,151 |
Unlevered Free Cash Flow | 6,310 | 5,868 | 4,394 | 4,869 | -2,026 | 1,154 |
Change in Working Capital | 2,207 | 2,207 | 346.19 | 2,437 | -2,835 | -530.01 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.